A 12-week Phase 2/3 Double-masked, Randomized, Multicenter Study of OCS-01 OPTIREACH® Topical Dexamethasone Eye Drops in Subjects with Diabetic Macular Edema (DME): Efficacy and Safety Findings (ARVO 2024) - Apr 15, 2024 - Abstract #6256 - B0166; Pres time: May 9, 2024; 11:45 AM - 01:30 PM; Location: Exhibit Hall - Seattle Convention Center; B0166; "The study successfully met both primary and secondary endpoints in a statistically significant manner. OCS-01 demonstrated strong efficacy and was well-tolerated. Induction with 6 drop/day and maintenance with 3 drops/day was an effective dosing regimen.The positive results support the progression of the DIAMOND program, with two parallel global phase 3 studies."
Clinical • P2/3 data • Diabetic Macular Edema • Ophthalmology
|
|
Sunil S. Patel1; Ramin Tadayoni2; David S. Boyer3; Sabri Markabi4; Bastian Dehmel5; Pravin Dugel6; Arshad M. Khanani7
|